Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features by Palomo Sanchis, Laura et al.
Oncotarget57021www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 35
Targeted deep sequencing improves outcome stratification in 
chronic myelomonocytic leukemia with low risk cytogenetic 
features
Laura Palomo1,2, Olga Garcia3, Montse Arnan4, Blanca Xicoy3, Francisco Fuster1, 
Marta Cabezón3, Rosa Coll5, Vera Ademà1, Javier Grau3, Maria-José Jiménez3, 
Helena Pomares4, Sílvia Marcé3, Mar Mallo1, Fuensanta Millá3, Esther Alonso4, 
Anna Sureda4, David Gallardo5, Evarist Feliu3, Josep-Maria Ribera3, Francesc Solé1, 
Lurdes Zamora3
1MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat 
Autònoma de Barcelona, Badalona, Spain
2Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Badalona, Spain
3Hematology Service, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat 
Autònoma de Barcelona, Badalona, Spain
4Hematology Service, ICO-Hospital Duran i Reynals, Barcelona, Spain
5Hematology Service, ICO-Hospital Josep Trueta, Girona, Spain
Correspondence to: Lurdes Zamora, email: lzamora@iconcologia.net
Keywords: chronic myelomonocytic leukemia, normal karyotype, gene mutations, targeted deep sequencing, prognostic factors
Received: May 20, 2016    Accepted: July 01, 2016    Published: July 29, 2016
ABSTRACT
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic 
myelomonocytic leukemia (CMML), while gene mutations are present in >90% of 
cases. Patients with low risk cytogenetic features account for 80% of CMML cases 
and often fall into the low risk categories of CMML prognostic scoring systems, 
but the outcome differs considerably among them. We performed targeted deep 
sequencing of 83 myeloid-related genes in 56 CMML patients with low risk cytogenetic 
features or uninformative conventional cytogenetics (CC) at diagnosis, with the aim 
to identify the genetic characteristics of patients with a more aggressive disease. 
Targeted sequencing was also performed in a subset of these patients at time of 
acute myeloid leukemia (AML) transformation. Overall, 98% of patients harbored 
at least one mutation. Mutations in cell signaling genes were acquired at time of 
AML progression. Mutations in ASXL1, EZH2 and NRAS correlated with higher risk 
features and shorter overall survival (OS) and progression free survival (PFS). 
Patients with SRSF2 mutations associated with poorer OS, while absence of TET2 
mutations (TET2wt) was predictive of shorter PFS. A decrease in OS and PFS was 
observed as the number of adverse risk gene mutations (ASXL1, EZH2, NRAS and 
SRSF2) increased. On multivariate analyses, CMML-specific scoring system (CPSS) 
and presence of adverse risk gene mutations remained significant for OS, while CPSS 
and TET2wt were predictive of PFS. These results confirm that mutation analysis 
can add prognostic value to patients with CMML and low risk cytogenetic features or 
uninformative CC.
INTRODUCTION
Chronic myelomonocytic leukemia (CMML) is a 
hematopoietic stem cell disorder with features from both 
myelodysplastic syndromes (MDS) and myeloproliferative 
neoplasms (MPN) [1]. The original French-American-
British (FAB) criteria identifies two variants based on 
leukocyte count (myelodysplastic [<13×109/L], MD-
CMML, and myeloproliferative [>13×109/L], MP-CMML), 
while the 2008 World Health Organization (WHO) 
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classification distinguishes two categories (CMML-1 and 
CMML-2) according to blast percentage in bone marrow 
(BM) or peripheral blood (PB) [1,2]. Very recently, the 
2016 revision of the WHO criteria has proposed the 
inclusion of a third CMML subtype, CMML-0, based on 
recent findings that demonstrate that these three CMML 
subtypes have different clinical outcomes [3,4].
Clonal cytogenetic abnormalities are not frequent 
in CMML (20-30%), whereas gene mutations have 
been reported in >90% of patients at diagnosis [5–7]. 
Prognostic impact of cytogenetic alterations in CMML 
was first explored by the Spanish MDS group and recently 
reviewed by the Mayo Clinic-French Consortium [5, 8]. 
According to both studies, up to 80% of CMML patients 
present with low risk cytogenetic features (normal 
karyotype, isolated -Y or sole der(3q)).
During the past years, several studies have reported 
recurrent gene mutations in CMML, being mutations in 
TET2 (50-60%), ASXL1 (40-50%) and SRSF2 (40-50%) 
the most frequent [7, 9, 10]. Less frequent mutations 
(10-30%) have also been described in RUNX1, CBL, K/
NRAS, EZH2, UTX, DNMT3A and JAK2 genes [6, 7, 
10–12]. Prognostic relevance of mutations in ASXL1, 
TET2, RUNX1, CBL and NRAS has been demonstrated 
on univariate survival analyses on CMML [7, 13, 14], 
but only ASXL1 mutations seem to retain this impact on 
multivariate models [15, 16].
Several prognostic scoring systems have been 
proposed for CMML in the past years. The CMML-
specific scoring system (CPSS) was developed by the 
Spanish MDS group and includes CMML-2, MP-CMML, 
transfusion dependency and cytogenetic risk stratification 
as independent adverse prognostic factors [17]. Other 
novel CMML-specific scoring systems, like the Groupe 
Francophone des Myélodysplasies (GFM) CMML 
model [15] and the Molecular Mayo model [16], include 
similar biological parameters but exclude cytogenetic 
abnormalities. These two models introduce for the first 
time the use of molecular criteria, such as the presence of 
mutations in ASXL1.
A significant subset of CMML patients fall into the 
low risk cytogenetic category and most of them present 
with normal karyotype, but the median overall survival 
(OS) and the risk of AML progression differ considerably 
among them [17]. With the aim to identify a subgroup of 
patients with a more aggressive disease, we performed 
targeted deep sequencing in 56 patients with CMML 
and low risk cytogenetic features or no metaphases and 
explored the prognostic value of gene mutations.
RESULTS
Characteristics of CMML patients
A total of 56 patients with CMML and low risk 
cytogenetic features or uninformative conventional 
cytogenetics (CC) were included in the study. Median 
follow-up of alive patients was 36 months (range, 5.8 to 
83.5 months). Main clinical and biological characteristics of 
patients are summarized in Table 1. Median age at diagnosis 
was 72 years and the series included 37 (66%) males and 19 
(34%) females. Following the FAB criteria [2], 46 (82%) 
patients were classified as MD-CMML and 10 (18%) as MP-
CMML, while according to the 2008 WHO classification 
[1], 49 (87%) cases corresponded to CMML-1 and 7 (13%) 
to CMML-2. Progression to AML was observed in 16 (29%) 
patients. Risk stratification of patients was based on the 
CPSS [17] and the GFM CMML model [15] (Table 1).
Conventional cytogenetics
Conventional cytogenetics was performed in 
all patients at diagnosis (n=56) and in 12 patients at 
the time of AML transformation. All patients had low 
risk cytogenetic features at diagnosis (51 with normal 
karyotype and three with isolated -Y) except for two cases 
in which no metaphases were obtained, therefore being 
considered as uninformative for CC (Table 1). At the 
time of AML progression, 6 (50%) patients still presented 
with normal karyotype, while the other 6 (50%) cases 
had acquired chromosomal aberrations. In 4 out of these 
6 patients, these corresponded to high risk cytogenetic 
abnormalities according to CPSS [5].
Targeted deep sequencing
Targeted deep sequencing was performed in a total 
of 64 samples, with a mean depth per base per sample of 
1256-fold (1256x). More than 95% of the target sequences 
were analyzed with >100 independent reads and >99% 
with at least 30 reads. After excluding sequencing and 
mapping errors a mean of 299 single nucleotide variants 
(SNVs) and insertions/deletions (indels) were called per 
sample. After filtering non-silent variants and excluding 
known polymorphisms, a mean of 4 variants per sample 
were called as high-probability somatic changes.
Spectrum of gene mutations at diagnosis
Across the entire cohort, 98% (55/56) of 
patients harbored at least one mutation. Details of 
all the variants detected in the series can be seen in 
Supplementary Table S1. Overall, 2 (4%) patients 
had 1 mutation, 5 (9%) had 2 concurrent mutations, 
12 (21%) had 3, 15 (27%) had 4, 11 (20%) had 5, 8 
(14%) had 6, and 2 (4%) had 8 (Supplementary Figure 
S1A). Distribution of the detected mutations across 
the CMML patients are described in Figure 1. Most 
frequently affected genes (in >10% of patients) were 
TET2 (71%), ASXL1 (43%) and SRSF2 (36%); followed 
by RUNX1 (23%), ZRSR2 (16%), CBL (13%) and 
NRAS (13%). Mutations detected in 5-10% of patients 
were found in the following genes: EZH2, CREBBP, 
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Table 1: Main clinical and hematological characteristics of CMML patients at diagnosis (n=56)
Variable Median (range) N (%)
Age, years
 <70
 ≥70
72 (48-89) 22/56 (39)
34/56 (61)
Gender
 Male
 Female
37/56 (66)
19/56 (34)
FAB classification
 Myelodysplastic (CMML-MD)
 Myeloproliferative (CMML-MP)
46/56 (82)
10/56 (18)
WHO classification
 CMML-1
 CMML-2
49/56 (87)
7/56 (13)
Hemoglobin level, g/dL
 <10
 ≥10
12.1 (7.2-16.1) 8/56 (14)
48/56 (86)
Leukocyte count, x109/L
 <13
 ≥13
8.0 (3.2-45.0) 46/56 (82)
10/56 (18)
Platelet count, x109/L
 <100
 ≥100
139.0 (25.0-481.0) 18/56 (32)
38/56 (68)
Neutrophil count, x109/L
 <1.8
 ≥1.8
4.1 (0.8-30.2) 9/56 (16)
47/56 (84)
Blasts in BM, %
 <10
 ≥10
2.0 (0.0-15.0) 53/56 (95)
3/56 (5)
RBC transfusion dependency
 No
 Yes
50/56 (89)
6/56 (11)
Splenomegaly
 No
 Yes
34/43 (79)
9/43 (21)
Cytogenetics
 Normal karyotype
 Isolated -Y
 Uninformative CC
51/56 (91)
3/56 (5)
2/56 (4)
CPSS risk group [17]
 Low
 Intermediate-1
 Intermediate-2
42/56 (75)
9/56 (16)
5/56 (9)
GFM CMML model [15]
 Low
 Intermediate
 High
37/56 (66)
17/56 (30)
2/56 (4)
(Continued )
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UMODL1, SETBP1, SH2B3, NF1, IDH2, SF3B1, 
KMT2D, CSF3R, JAK2, PTPN11, SMC1A, U2AF1 and 
DNMT3A (Supplementary Figure S1B). The list of all 
the affected genes can be seen in Supplementary Table 
S2, and the mutation type distribution according to each 
affected gene can be seen in Supplementary Figure 
S1C. Most of these genes are involved in cell signaling, 
epigenetic mechanisms and spliceosome machinery 
(Supplementary Figure S1D). We then examined the 
correlation between gene mutations in order to identify 
possible functional interactions across the different 
affected genes. All genes were included in all statistical 
analyses, but to ensure a minimum statistical accuracy, 
from now on we will focus on mutations detected in 
at least 5 patients. Mutations in ASXL1 frequently 
co-occurred with mutations in NRAS (P=0.035) and 
EZH2 (P=0.011). A positive correlation was also found 
between RUNX1 and CBL (P=0.043). Finally, mutations 
in SRSF2 correlated with mutations in CBL (P=0.043), 
but were mutually exclusive with mutations in ZRSR2 
(P=0.019).
Coexistence of gene mutations and loss of 
heterozygosity
Most of the patients in this cohort (n=48/56, 
85.7%) had been previously studied by our group 
using single nucleotide polymorphism arrays (SNP-A) 
[18]. Therefore, we investigated whether some of the 
mutations detected in the present study correlated with 
the alterations previously detected by SNP-A. Interstitial 
copy number neutral loss of heterozygosity (CNN-LOH) 
was detected in 14 of these patients, 10 of which also 
presented with one mutation affecting a gene located in 
the region with CNN-LOH. All patients (n=4) with CNN-
LOH in 4q24q35 region harbored a TET2 mutation; 
Variable Median (range) N (%)
Progression to AML
 No
 Yes
40/56 (71)
16/56 (29)
BM: bone marrow; RBC: red blood cell; Uninformative CC: cases with no metaphases; AML: acute myeloid leukemia
Figure 1: Distribution of the affected genes across the 56 CMML patients at diagnosis. One gene is represented in each line 
and one patient in each column. Bars at the right represent the number of mutations present in each gene, while columns at the top represent 
the number of mutations per patient. At the bottom correlations of mutations with WHO, FAB, AML progression, CPSS and CFM model.
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all patients (n=3) with CNN-LOH in 11q13.3q25 had 
a mutation in CBL; one patient with CNN-LOH in 
7q22.1q36.3 showed a EZH2 mutation, another one 
with CNN-LOH in 12q21.2q24.33 had a KRAS mutation 
and one patient with CNN-LOH in 17q25.3 harbored a 
SRSF2 mutation (Supplementary Table S3). Interstitial 
CNN-LOH from the four remaining patients affected 
regions that did not include any of the studied genes 
(Supplementary Table S3).
Acquisition of mutations during AML 
progression
Targeted deep sequencing was performed at time 
of AML transformation in seven patients and at time of 
CMML-2 progression in one patient. The spectrum of 
mutations detected per patient was different between 
diagnosis and AML progression for all except from 
one patient. In the case that evolved from CMML-1 to 
CMML-2 it did not differ (Table 2). Number of mutations 
per patient was higher at time of AML progression in 5/7 
(71.4%) patients. Considering alterations detected by 
both CC and sequencing, median number of alterations 
at time of progression was higher than at diagnosis (5 
alterations at progression vs. 3 alterations at diagnosis, 
P=0.017). Mutations acquired in all but one patient 
that progressed to AML affected genes involved in cell 
signaling pathways that affect cell division, growth, 
differentiation and survival; such as BRAF, FLT3, KRAS, 
PTPN11 and NRAS. Of note, the remaining patient 
that progressed to AML did not acquire any additional 
mutation, but presented with the intermediate cytogenetic 
abnormality t(8;16)(p11;13), detected by CC at time of 
AML progression.
Correlations between gene mutations and 
clinical variables
We investigated the correlation between mutations 
detected at diagnosis and main clinical and biological 
parameters of the patients, including age, sex, CMML 
FAB and WHO subtypes, BM and PB cell counts, RBC 
transfusion dependency, presence of splenomegaly, CPSS 
and GFM models and progression to AML. Mutations 
in EZH2 gene associated with WHO 2008 CMML-2 
subtype (P=0.011), FAB CMML-MP subtype/leukocyte 
count (P=0.035) and higher risk groups according to 
CPSS (P<0.001) and GFM (P=0.001) models. Mutations 
in NRAS correlated with FAB CMML-MP subtype/
leukocyte count (P=0.015), presence of splenomegaly 
(P>0.001) and age <70 years (P=0.012). ASXL1 
mutations associated with AML progression (P=0.034), 
age <70 years (P=0.015) and higher risk groups 
according to the CPSS (P=0.014) and GFM (P=0.001) 
models. SRSF2 mutations correlated with platelet count 
<100 x109/L and higher risk groups according to GFM 
model (P=0.025). Even though JAK2 mutations were 
only present in three patients, it is worth highlighting, 
because it has been previously reported [19], that they 
associated with FAB CMML-MP subtype/leukocyte 
count (P=0.004). Interestingly, mutations in TET2 gene 
were the only ones associated with good prognosis 
features, such as Hemoglobin>10g/dL (P=0.005), not 
progression to AML (P=0.008) and lower risk groups 
according to CPSS (P=0.036).
Univariate survival analyses
We then explored the impact of clinical, biological 
and genetic data on patients’ outcome (Table 3). Median 
OS and progression free survival (PFS) of the cohort 
were 47 months (IC95% 15-79) and 128 months (NA), 
respectively. The following clinical and biological 
variables were predictive of both OS and PFS: CMML 
WHO subtype, CMML FAB subtype, transfusion 
dependency, presence of splenomegaly, hemoglobin level, 
leukocyte count, CPSS risk group, alternative CPSS risk 
group and GFM CMML model. In addition, BM blast 
percentage and age were also predictive of PFS. Regarding 
genetic features, total number of mutations was predictive 
of OS and PFS when patients were stratified into the 
following subgroups: 0-3 mutations, 4-5 mutations, >5 
mutations (Table 3, Supplementary Figure S2A). Focusing 
on specific genes, mutations in ASXL1, NRAS and EZH2 
associated with both shorter OS and PFS. Furthermore, 
mutations in SRSF2 only associated with inferior OS, 
while absence of TET2 mutations (TET2wt) associated 
with inferior PFS but did not correlate with OS (Table 
3, Supplementary Figure S2B). Overall, 34/56 (61%) 
of patients presented with at least one adverse risk gene 
mutation (ASXL1, EZH2, NRAS and SRSF2). Presence 
of a mutation in one of these genes correlated with both 
shorter OS and PFS (Table 3, Figure 2A). Moreover, a 
decrease in OS and PFS was observed as the number of 
adverse risk mutations increased. Patients were classified 
in three groups according to the number of mutations 
in these genes (0, 1, ≥2), which associated with poorer 
OS and PFS (Table 3, Figure 2B). Even when patients 
were classified in four groups (0, 1, 2, ≥3), the statistical 
association was maintained (Table 3, Supplementary 
Figure S2C). Recently, Patnaik et al. reported a prognostic 
interaction between ASXL1 and TET2 mutations in CMML 
[6], confirming the negative impact in OS imparted by 
ASXL1 mutations and suggesting a favorable impact 
from TET2 mutations in the absence of ASXL1 mutations. 
We investigated this interaction in our cohort of patients 
and observed that the different combinations between 
ASXL1 and TET2 mutations were able to stratify patients 
in subgroups with significantly different OS (Table 3, 
Supplementary Figure S2D). Regarding PFS, patients with 
mutations only in TET2 presented a better outcome, but we 
observed a high overlap between the rest of the categories 
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Table 2: List of affected genes in CMML patients that were studied at diagnosis and at time of AML or CMML-2 
progression (n=8)
Data at diagnosis Data at progression
Diagnosis N of genes Gene Mutation 
Freq. (%)
Progression N of genes Gene Mutation 
Freq. (%)
CMML-1 5 SETBP1 45 CMML-2 5 SETBP1 49
UMODL1 46 UMODL1 47
SH2B3 43 SH2B3 41
SF3B1 48 SF3B1 45
GATA2 46 GATA2 41
CMML-1 5 ASXL1 49 AML 5 ASXL1 47
UMODL1 50 UMODL1 51
CDH3 40 CDH3 20
NRAS 15 NRAS 6
PTPN11 6
BRAF 9
CMML-1 2 RUNX1 52 AML 4 RUNX1 52
TET2 45 TET2 43
SRSF2 24
FLT3 22
CMML-1 3 TET2 47 AML 6 TET2 48
CBL 36 CBL 5
ASXL1 43 ASXL1 46
KMT2D 51
KRAS 42
AEBP2 32
CMML-2 3 JARID2 51 AML 4 JARID2 48
TET2 44 TET2 43
NPM1 31 NPM1 30
GNAS 20
CMML-2 6 ASXL1 52 AML 6 ASXL1 49
CSF3R 51 CSF3R 47
SRSF2 41 SRSF2 12
TET2 44 TET2 46
NRAS 47 NRAS 47
EZH2 39 EZH2 43
CMML-2 2 ASXL1 43 AML 4 ASXL1 48
ZRSR2 19 ZRSR2 22
KMT2D 22
PTPN11 9
(Continued )
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Data at diagnosis Data at progression
Diagnosis N of genes Gene Mutation 
Freq. (%)
Progression N of genes Gene Mutation 
Freq. (%)
CMML-2 3 ASXL1 34 AML 4 ASXL1 39
RUNX1 45 RUNX1 50
NF1 6 NF1 8
NRAS 5
Genes that are only affected at time of diagnosis or progression are highlighted in bold
Table 3: Overall survival analyses and progression free survival according to the main clinical, hematological and 
genetic characteristics of CMML patients at diagnosis (n=56)
Variable Overall survival (OS) Progression free survival (PFS)
3 year % OS (95% 
CI)
Log-rank P value 3 year % PFS (95% 
CI)
Log-rank P value
WHO classification
 CMML-1
 CMML-2
57 (41, 73)
29 (0, 63) 0.020
75 (60, 90)
19 (0, 52) <0.001
FAB classification
 MD-CMML
 MP-CMML
61 (45, 77)
23 (5, 51) 0.007
74 (59, 89)
38 (1, 75) 0.036
Sex
 Male
 Female
50 (32, 68)
61 (34, 84) 0.246
68 (50, 86)
68 (44, 92) 0.916
Age (years)
 <70 years
 ≥70 years
37 (14, 60)
64 (47, 81) 0.322
42 (18, 67)
85 (71, 99) 0.003
Hemoglobin level
 <10 g/dL
 ≥10 g/dL
17 (0, 46)
60 (45, 75) 0.045
42 (2, 82)
72 (57, 87) 0.009
Leukocyte count
 <13×109/L
 ≥13×109/L
61 (45, 77)
23 (5, 51) 0.007
74 (59, 89)
38 (1, 75) 0.036
Platelet count
 <100×109/L
 ≥100×109/L
53 (27, 79)
54 (37, 71) 0.797
58 (31, 85)
72 (55, 89) 0.302
Neutrophil count
 <1,8×109/L
 ≥1,8×109/L
65 (33, 97)
52 (36, 58) 0.880
73 (41, 100)
66 (50, 82) 0.956
Blasts in BM
 <5%
 ≥5%
58 (42, 74)
40 (10, 70) 0.499
76 (61, 91)
40 (10, 70) 0.008
Splenomegaly
 Absent
 Present
68 (52, 84)
0 (NA) 0.001
78 (62, 94)
0 (NA) 0.004
(Continued )
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Variable Overall survival (OS) Progression free survival (PFS)
3 year % OS (95% 
CI)
Log-rank P value 3 year % PFS (95% 
CI)
Log-rank P value
Transfusion 
requirement
 Independent
 Dependent
65 (50, 80)
0 (NA) 0.001
74 (59, 89)
0 (NA) 0.010
CPSS
 Low
 Intermediate-1
 Intermediate-2
63 (47, 79)
50 (15, 85)
0 (NA)
<0.001
81 (67, 95)
39 (5, 73)
0 (NA)
<0.001
Alternative CPSS
 Low
 Intermediate-1
 Intermediate-2
70 (53, 87)
26 (2, 50)
25 (0, 58)
0.005
82 (67, 97)
39 (6, 72)
25 (0, 68)
<0.001
GFM CMML model
 Low
 Intermediate
67 (50, 84)
31 (6, 56)
0 (NA)
<0.001
79 (64, 94)
42 (8, 76)
0 (NA)
<0.001
Number of mutations
 0-3
 4-5
 >5
70 (48, 92)
61 (39, 83)
10 (0, 29)
<0.001
75 (53, 97)
80 (61, 99)
15 (0, 42)
0.001
ASXL1
 Wild-type
 Mutated
69 (52, 86)
30 (2, 52) 0.027
81 (66, 96)
45 (13, 77) 0.015
NRAS
 Wild-type
 Mutated
62 (47, 77)
0 (NA) <0.001
74 (59, 89)
0 (NA) 0.005
EZH2
 Wild-type
 Mutated
58 (43, 73)
20 (0, 55) 0.002
72 (57, 87)
27 (0, 71) 0.004
SRSF2
 Wild-type
 Mutated
64 (47, 81)
35 (12, 58) 0.049
69 (52, 86)
65 (37, 93) 0.835
TET2
 Wild-type
 Mutated
41 (14, 68)
59 (42, 76) 0.476
41 (14, 68)
80 (65, 95) 0.005
Presence of adverse 
risk gene mutationsa
 No
 Yes
81 (64, 98)
35 (16, 54) 0.008
85 (69, 100)
52 (29, 75) 0.031
Number of adverse 
risk gene mutationsa
 0
 1
 ≥2
81 (64, 98)
53 (25, 81)
16 (0, 36)
<0.001
85 (69, 100)
62 (32, 92)
48 (19, 77)
0.030
(Continued )
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(Table 3, Supplementary Figure S2D). In order to delineate 
the benefit of TET2 mutations related to other adverse 
mutations, we investigated the prognostic interaction 
between TET2 mutations and adverse risk genes excluding 
ASXL1, which was able to separate the patients in four 
distinct prognostic groups with clear different OS and PFS 
(Table 3, Supplementary Figure S2E). Overall, focusing 
on patients with mutations in one of these genes (EZH2, 
NRAS or SRSF2), regardless of TET2 status, they had an 
unfavorable prognosis, even though patients with TET2 
mutations showed a better prognosis in this subset. On the 
other hand, in the absence of adverse risk gene mutations, 
patients with TET2 mutations again had a better outcome 
than patients without, suggesting a protective role for 
TET2 mutations.
Multivariate survival analyses
Finally, we performed an adjusted multivariate 
analysis including clinical, biological and genetic features 
that were statistically significant in the univariate analyses 
(Table 4). For OS, the variables that remained significant 
in the multivariate model, taking as baseline the low risk 
group, were the CPSS scoring system and the presence of 
at least one adverse risk gene mutation (ASXL1, EZH2, 
NRAS, SRSF2). Regarding PFS multivariate analysis, the 
following variables remained significant in the model: 
CPSS scoring system and the absence of a TET2 mutation 
(TET2wt).
DISCUSSION
Over the past few years, next-generation sequencing 
(NGS) has led to a revolution in the study of hematological 
malignancies, with remarkable efforts to characterize the 
genetic basis of these disorders. In the field of CMML 
recent studies have reported mutations in >90% of 
patients, affecting genes mainly involved in the following 
mechanisms: epigenetic regulation (TET2, ASXL1, EZH2, 
DNMT3A, IDH1/2), spliceosome machinery (SRSF2, 
ZRSR2, SF3B1, U2AF1), cell signaling and transcription 
factor regulation (NRAS, KRAS, CBL, JAK2, RUNX1) 
[6, 7, 11, 15, 20, 21]. Mutations in ASXL1, SRSF2, CBL, 
IDH2, EZH2, DNMT3A, NRAS and RUNX1 have been 
associated, in some of these studies, with poorer OS or 
increased risk of AML progression [6, 7, 11, 14, 15, 21–
24]. However, up to date, the only gene that has shown to 
correlate with worse outcome on multivariate models is 
ASXL1 [15, 16].
Cytogenetic abnormalities are not common in 
CMML (20-30%), but when present they confer a 
Variable Overall survival (OS) Progression free survival (PFS)
3 year % OS (95% 
CI)
Log-rank P value 3 year % PFS (95% 
CI)
Log-rank P value
Number of adverse 
risk gene mutationsa
 0
 1
 2
 ≥3
81 (64, 98)
53 (25, 81)
20 (0, 44)
0 (NA)
0.001
85 (69, 100)
62 (32, 92)
54 (22, 86)
0 (NA)
0.047
Combination of TET2 
and ASXL1 mutations
 TET2mut-ASXL1wt
 TET2wt-ASXL1mut
 TET2wt-ASXL1wt
 TET2mut-
ASXL1mut
78 (61, 95)
47 (10, 84)
34 (0, 72)
20 (0, 44)
0.001
96 (16, 100)
47 (10, 84)
36 (0, 75)
42 (3, 81)
0.004
Combination of TET2 
and AR gene mutations 
(excluding ASXL1)
 TET2mut-ARwt
 TET2wt-ARwt
 TET2mut-ARmut
 TET2wt-ARmut
83 (65, 100)
64 (31, 97)
35 (12, 58)
0 (NA)
0.001
88 (72, 100)
64 (31, 97)
76 (55, 97)
0 (NA)
<0.001
a: ASXL1, EZH2, NRAS, SRSF2; BM: bone marrow
CI: confidence interval; NA: Not applicable; AR genes (excluding ASXL1): adverse risk genes EZH2, NRAS and SRSF2. 
Variables with significant impact (P<0.05) in overall survival or progression free survival are highlighted in bold.
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significant adverse outcome, except for isolated -Y [5, 
8]. Patients with low risk cytogenetic features (normal 
karyotype and isolated -Y) account for approximately 
80% of CMML cases and often fall into the low risk 
categories of CMML prognostic scores, but the OS and 
risk of AML transformation differs considerably among 
them [17]. Therefore, we have focused our study on 56 
CMML patients with low risk cytogenetic abnormalities 
or no metaphases, since CC does not provide prognostic 
information in all these cases. Our aim is to identify, in 
this cytogenetically homogeneous cohort, the genetic 
characteristics of the subset of patients that present with a 
more aggressive disease.
By performing targeted deep sequencing using 
a panel of 83 myeloid-related genes, we have detected 
mutations in 98% of CMML patients at diagnosis. 
Spectrum of gene mutations does not differ from the ones 
reported in more heterogeneous CMML cohorts [6, 7, 11, 
15]. This study confirms the molecular heterogeneity of 
the disease. In addition, in the current study, we report 
for the first time recurrent mutations (5-10%) in CMML 
in the genes CREBBP, KMT2D and UMODL1, which 
have been previously reported in lymphoid neoplasms 
or solid tumors [25, 26]. Studies in larger cohorts should 
provide more insights in the involvement of these genes in 
the pathogenesis of CMML. On the other hand, although 
multiple mutations in different genes can be detected in 
most of CMML patients, it is interesting to point out that 
91% of patients are characterized by harboring a mutation 
in at least one of the three most recurrent genes in CMML 
(TET2, ASXL1, SRSF2), which can be used for diagnostic 
purposes.
Across the entire cohort, 14/48 (29.2%) patients 
presented with interstitial CNN-LOH, as previously 
reported by our group [18]. All patients with CNN-LOH 
in 4q24 harbored a TET2 mutation and all cases with 
CNN-LOH in 11q23.3 presented with a CBL mutation, 
confirming the association between both types of 
molecular events [27, 28]. Similarly, single patients with 
EZH2, NRAS and SRSF2 mutations also presented CNN-
Figure 2: Prognostic impact of gene mutations. A. OS and PFS curves according to presence or absence of an adverse risk gene; 
B. OS and PFS curves according to number of mutations in an adverse risk gene. See Table 3 for 3-year percentage overall survival and 
progression free survival and confidence intervals. AR mutations: adverse risk gene mutations (ASXL1, EZH2, NRAS, SRSF2).
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LOH in 7q35-q36, 12p12.1 and 17q25.3, respectively, 
suggesting that detection of CNN-LOH in CMML 
indicates the presence of homozygous mutations in genes 
located in the affected region. The negative impact of 
CNN-LOH observed in CMML [18] may be influenced 
or even enhanced by the presence of mutations in genes 
located in these regions.
Targeted sequencing was also performed in seven 
patients at time of AML progression and revealed the 
acquisition of additional mutations in 6/7 (85.7%) patients, 
all of them with at least one mutation in a gene involved 
in cell signaling. Five of these patients acquired mutations 
in components or regulators of the RAS signaling pathway 
(KRAS, NRAS, PTPN1, BRAF and FLT3), suggesting that 
activation of RAS pathway is probably involved in the 
evolution of CMML in some patients. Mutations in these 
genes have been previously associated with CMML-MP 
[14, 23]. The remaining patient acquired a mutation in 
GNAS, a gene involved in the GPCR signaling pathway. 
Somatic activating mutations in GNAS are common 
in solid tumors but were recently identified for the first 
time in hematological neoplasms, in 1% of MDS [29]. 
Implication of GNAS mutations in MDS or related myeloid 
neoplasms has not been further investigated. In our study, 
mutations in ASXL1 and TET2wt at diagnosis correlated 
with AML progression. This association has already 
been reported for ASXL1 mutations [14, 15]. Thus, even 
though acquisition of cell signaling mutations involved in 
AML progression cannot be anticipated, presence of other 
mutations at diagnosis may predict AML transformation 
and serve as prognostic markers for a closer monitoring of 
these patients or to be considered as candidates to a more 
aggressive treatment.
Correlation analyses between clinical and biological 
features and gene mutations revealed interesting 
associations. Of note, adverse risk genes such as ASXL1, 
EZH2 and TET2wt, were in many cases associated with 
high risk parameters, such as CMML-2, lower Hg levels, 
higher leukocyte counts, higher risk groups of CPSS and 
GFM models or progression to AML. In addition, as 
expected, myeloproliferative features such as CMML-
MP variant, leukocyte count or presence of splenomegaly, 
correlated with genes involved in cell signaling, such as 
NRAS and JAK2.
The prognostic value of individual gene mutations 
was explored by performing survival analyses and 
investigating correlation with clinical features. Mutations 
in ASXL1, EZH2, NRAS and SRSF2 correlated with 
different clinical or biological features that are known 
to be associated with worse outcome in CMML [15–
17]. Mutations in these four genes were associated 
with shorter OS in univariate survival analyses and all, 
except from SRSF2, correlated with shorter PFS as well. 
Some of these associations have already been reported, 
but ASXL1 is the only marker that has been shown to be 
prognostically detrimental on multivariate models [6, 15, 
24]. Therefore, impact on presenting one or more adverse 
risk gene mutations (ASXL1, EZH2, NRAS, SRSF2) was 
investigated. Presence of mutations in at least one of these 
genes was predictive of both OS and PFS and was the 
only variant that remained significant in OS multivariate 
model in addition to CPSS. Of note, number of adverse 
risk gene mutations was also predictive of OS and PFS 
when patients were classified in three (0, 1, ≥2) and 
four (0, 1, 2, ≥3) subgroups, which suggests an additive 
negative impact of presenting mutations in these genes. 
Interestingly, survival outcomes were also affected by 
the number of total concurrent mutations, meaning that 
each acquired mutation confers an additional detrimental 
value, as has been reported in MDS and MPN [12, 
30]. Focusing on PFS, TET2wt was also predictive of 
shorter PFS, supporting the favorable impact of TET2 
Table 4: Multivariate model including clinical, biological and genetic characteristics of CMML patients at diagnosis 
(n=56)
Overall survival Progression free survival
Variable HR 95% CI P Variable HR 95% CI P
CPSSa:
 Int-1
 Int-2
1.2
6.2
0.4 to 3.4
2.0 to 18.8
0.005
0.695
0.001
CPSSa:
Int-1
Int-2
2.7
16.5
0.8 to 8.7
3.4 to 79.4
0.002
0.093
<0.001
Presence 
of adverse 
risk gene 
mutationsb,c
2.9 1.0 to 8.2 0.042 TET2 wtd 4.1 1.3 to 12.8 0.013
a: Reference category: Low risk
b: ASXL1, EZH2, NRAS, SRSF2
c: Reference category: No mutations
d: Reference category: TET2 mutation
CI: confidence interval
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mutations that has been previously reported but remains 
controversial [5, 13, 27, 28]. Of note, we detected TET2 
mutations at a higher frequency than the one reported in 
other studies [31-33]. Considering that TET2 mutations 
are associated with good prognosis features and may play 
a protective role in CMML, this higher frequency could 
be explained due to the fact that our cohort of patients 
is focused on lower risk CMML. Patnaik et al recently 
reported a prognostic interaction between ASXL1 and 
TET2 mutations, and suggested a favorable impact from 
TET2 mutations in the absence of ASXL1 mutations 
[6]. We investigated this interaction in our cohort and 
observed that the classification of patients according to 
the status of these two genes was associated with OS 
and PFS. Even though the four survival curves did not 
match the ones reported by Patnaik et al, probably due 
to the limited number of patients in our cohort in the 
middle subgroups (TET2wt-ASXL1mut and TET2wt-
ASXL1wt), we did confirm the significant negative 
impact of ASXL1 mutations and the favorable impact 
of TET2 mutations in the absence of ASXL1 mutations. 
Interestingly, the group of TET2wt-ASXL1wt had a quite 
unfavorable prognosis, worse than the TET2-wt/ASXL1-
mut, which is what Patnaik et al described and what 
would be expected. This could be explained because 
some of the patients in the TET2wt-ASXL1wt group (n=7) 
carry mutations in other adverse risk genes. Specifically, 
two of them carried SRSF2 mutations and two carried 
RUNX1 mutations, which also have been reported to have 
an adverse prognostic impact, even though this was not 
confirmed in our cohort [15]. The prognostic interaction 
between TET2 and other adverse risk gene mutations was 
also analyzed. The analysis confirmed that the negative 
impact of mutations in adverse risk genes prevails over 
TET2 mutations, although patients with TET2 mutations 
have a better outcome compared to patients without, 
suggesting a protective role for TET2 mutations. The 
analysis also revealed that in the absence of adverse risk 
gene mutations, TET2 mutations confer the best outcome. 
This beneficial impact of TET2 mutations was even more 
noticeable in the PFS analysis, which Patnaik et al did 
not report. Furthermore, TET2wt was the only significant 
variant in the PFS multivariate model in addition to CPSS.
Although our series is limited by the number of 
samples compared to other series, it is the only one mainly 
focused on CMML patients with low risk cytogenetic 
features. In addition, the results of multivariate analyses 
for both OS and PFS suggest that our findings may be 
applicable to larger series of patients. Our multivariate 
model confirms the prognostic impact of the CPSS scoring 
system for both OS and PFS and implies that molecular 
studies can add prognostic value to this model, especially 
in patients with low risk cytogenetic features (normal 
karyotype, isolated -Y) or uninformative CC.
In summary, we report mutations in nearly all 
patients with CMML and low risk cytogenetic features, 
some of which have a negative impact on the outcome 
of patients. With NGS technologies being more 
accessible each day, we would recommend to perform 
targeted molecular analysis of ASXL1 and, if possible, 
EZH2, NRAS, SRSF2 and TET2 in patients with CMML 
and low risk cytogenetic features or uninformative CC. 
This may allow to identify patients that are more likely 
to present with an aggressive disease evolution and 
that could benefit from closely monitoring and more 
intensive treatments.
MATERIALS AND METHODS
Patients and samples
A retrospective study was performed on a total of 
56 patients with CMML from Institut Català d’Oncologia 
(ICO). Patients were diagnosed according to the FAB [2] 
and 2008 WHO [1] classifications. Cases with CMML and 
low risk cytogenetic features (normal karyotype or isolated 
-Y) or no metaphases at diagnosis were included in the 
study. Study approval was obtained from ICO-Hospital 
Germans Trias i Pujol Ethics Committee. Informed 
consent was obtained from all patients, in accordance with 
the Declaration of Helsinki.
Cytogenetics
Conventional G-banding cytogenetics was 
performed on bone marrow samples at diagnosis following 
standard procedures [5]. We analyzed 20 metaphases per 
sample (n=54) except in two cases in which no metaphases 
were obtained. Karyotypes were described according 
to the International System for Human Cytogenetic 
Nomenclature 2013 [34].
DNA samples
Samples were collected at diagnosis for all patients 
and at time of AML progression in 7 patients and CMML-
2 progression in one case. Whole bone marrow samples 
(n= 58) or peripheral blood (n=6) were used. Genomic 
DNA was extracted with QiaAmp DNA Blood Mini kit 
(Qiagen, Hilden, Germany) and quantified using Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen, CA, USA).
Targeted deep sequencing
Targeted deep-sequencing of a panel of 83 
myeloid-related genes was performed in all samples 
(Supplementary Table S4). Indexed libraries were prepared 
with 1μg of double strand genomic DNA using the Kapa 
Library Preparation Kit (Kapa Biosystems, MA, USA). 
Custom target capture enrichment using the SeqCap EZ 
capture chemistry (Nimblegen, Roche, Basel, Switzerland) 
was performed on pools of 8 libraries. Multiplexed 
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captured libraries were sequenced on an Illumina MiSeq 
following a 150bp paired-end reads standard protocol.
Targeted sequencing data analysis
Sequencing data were analyzed using an in-house 
pipeline. Reads were aligned against human genome 
build 19 (hg19) using BWA 0.7.12 [35]. Post-alignment 
including local indel realignment and base recalibration was 
performed using the tools in GATK 3.4.46 software package 
[36]. Packages SAMtools 1.2 and VarScan 2.4.0 were used 
for variant calling and ANNOVAR (version 2015Jun17) 
for variant annotation [37, 38]. High-probability oncogenic 
mutations were called by eliminating sequencing and 
mapping errors and by discarding variants located in highly 
variable regions or with low coverage, as well as SNPs 
described on the available databases and synonymous 
variants. Variants were also filtered according to the variant 
allele frequency (VAF): all variants with VAF ≥5% were 
reported, as well as variants with VAF<5% and at least 25 
reads for the variant that are known hotspots and have been 
reported in hematological neoplasms.
Statistical analysis
Baseline characteristics were described as 
frequency and percentage for categorical variables 
and median and range for quantitative variables. 
Comparisons of categorical variables between patient 
subsets were compared using χ2 or Fisher’s exact test, 
when appropriate, while median test was used to compare 
continuous variables. Comparisons of paired data for 
continuous variables were performed with the Wilcoxon 
test. OS was defined as time from diagnosis to the last 
follow-up or death from any cause and PFS as time from 
diagnosis to progression to AML (presence of ≥20% of 
blasts in bone marrow or peripheral blood) or death from 
CMML [39]. Survival curves were calculated using the 
Kaplan-Meier method and log-rank test was used for 
comparisons between groups. Multivariate analysis was 
performed using Cox proportional-hazards regression 
model, considering Wald Backward as selection method. 
Two-sided P values <0.05 were considered as statistically 
significant. The statistical package SPSS, version 23.0 
(SPSS Inc., Chicago, IL, USA) was used for all analyses.
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